Update on capecitabine alone and in combination regimens in colorectal cancer patients

Antonio Russo, Salvatore Pisconti, Daniela Petriella, Vito Lorusso, Fernando De Vita, Gianmauro Numico, Millaku, Amalia Azzariti, Saverio Cinieri, Evaristo Maiello, Stefania Tommasi, Nicola Silvestris, Colucci, Daniele Santini, Daniele Santini

Risultato della ricerca: Article

14 Citazioni (Scopus)

Abstract

Capecitabine is an orally administered fluoropyrimidine carbamate which has been developed as a prodrug of 5-FU with the goal to improve its tolerability and intratumoral drug concentration. The review aims to provide an evidence-based update of clinical trials investigating the clinical efficacy, adverse-event profile, dosage and administration of this drug, alone or in combination with conventional chemotherapeutics and/or new target-oriented drugs, in the management of colorectal cancer patients. © 2010 Elsevier Ltd.
Lingua originaleEnglish
pagine (da-a)S46-S55
Numero di pagine10
RivistaCancer Treatment Reviews
Volume36
Stato di pubblicazionePublished - 2010

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging

Fingerprint Entra nei temi di ricerca di 'Update on capecitabine alone and in combination regimens in colorectal cancer patients'. Insieme formano una fingerprint unica.

  • Cita questo

    Russo, A., Pisconti, S., Petriella, D., Lorusso, V., De Vita, F., Numico, G., Millaku, Azzariti, A., Cinieri, S., Maiello, E., Tommasi, S., Silvestris, N., Colucci, Santini, D., & Santini, D. (2010). Update on capecitabine alone and in combination regimens in colorectal cancer patients. Cancer Treatment Reviews, 36, S46-S55.